Back to Search
Start Over
Treatment of Wilsonʼs Disease with Triethylene Tetramine Hydrochloride (Trientine)
- Source :
- Journal of Pediatric Gastroenterology and Nutrition. 10:77-81
- Publication Year :
- 1990
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 1990.
-
Abstract
- Penicillamine is the drug of choice for the treatment of Wilson's disease, whatever the stage of the illness. Toxic manifestations may preclude the use of this life-saving drug in some patients and discontinuation of penicillamine therapy usually leads to death. We report our experience with Trientine in seven patients, aged 13 to 33 years, with Wilson's disease who developed toxic manifestations with penicillamine that required discontinuation of therapy. These include two with nephrosis, one with neutropenia, two with thrombocytopenia, and one each with a SLE-like and a Henoch-Schonlein-like syndrome. The patients were treated for periods from 6 weeks to 16 years with a dose of 0.5 to 2 g/day. Trientine proved to be an effective alternative copper chelating agent in the treatment of Wilson's disease in patients with penicillamine-induced neutropenia, thrombocytopenia, SLE, and nephrosis. No serious untoward side effects were noted.
- Subjects :
- Adult
Male
Drug
medicine.medical_specialty
Adolescent
media_common.quotation_subject
medicine.medical_treatment
Nephrosis
Administration, Oral
Neutropenia
Trientine
Gastroenterology
Hepatolenticular Degeneration
Internal medicine
medicine
Humans
media_common
Chemotherapy
business.industry
Penicillamine
Ethylenediamines
medicine.disease
Surgery
Discontinuation
Wilson's disease
Pediatrics, Perinatology and Child Health
Drug Evaluation
Female
business
Tetramine
medicine.drug
Subjects
Details
- ISSN :
- 02772116
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Journal of Pediatric Gastroenterology and Nutrition
- Accession number :
- edsair.doi.dedup.....4a45c115b11eb3c5f8eb1e4f2839c4b2